Michael P. Dillon

AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist

Joel R. Gever, Rothschild Soto, Robert Henningsen et al. · British Journal of Pharmacology · 2010 · 130 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Ying Huang, Jeff Zhang, Zhengtian Yu et al. · Journal of Medicinal Chemistry · 2017 · 103 citations · Full text

Medicine, Oncology, Pharmacology +17

Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild‐type and D79N α_2A‐adrenoceptor transgenic mice

Q‐M Zhu, John Lesnick, Jeffrey R. Jasper et al. · British Journal of Pharmacology · 1999 · 95 citations · Full text

Medicine, Pharmacology, Experimental Pharmacology +13

Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery

Peter S. Kutchukian, Nadya Vasilyeva, Jordan Xu et al. · PLoS ONE · 2012 · 88 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +15

35th Annual Meeting of the European Association for the Study of Diabetes

Arne Melander, Jonny Olsson, Gunnar Lindberg et al. · Diabetologia · 1999 · 86 citations

Medicine, Endocrinology, Internal Medicine +11